Similarly, the PFS and OS rates for patients with RUNX1::RUNX1T1, CBFB::MYH11, and biCEBPA were higher, and the prognosis for patients of the AML-MR and AML defined by differentiation subgroups was worse according to the 5th WHO classification (Figure 2B). Here, MYH11 is linked to acute myeloid leukemia.